AOD-9604 is a synthetic 16-amino-acid peptide studied for its effects on lipid metabolism, lipolysis, adipose tissue biology, and related metabolic pathways. It was developed from the lipolytic region of human growth hormone and has been investigated in both preclinical models and human clinical studies.
Research on AOD-9604 includes cellular and animal studies, pharmacological investigations, and clinical trials that evaluated its potential in obesity research. The available evidence is mixed: several preclinical studies reported effects on lipolysis, fat metabolism, and body weight, while later human development did not demonstrate sufficient efficacy for continued obesity drug development.
This guide brings together the current research on AOD-9604, including its molecular structure, proposed mechanisms, clinical evidence, stability considerations, and analytical testing.
What Is AOD-9604?
AOD-9604 is a synthetic peptide consisting of 16 amino acids. It is described in the scientific literature as an analogue of the lipolytic domain of human growth hormone.
Unlike full-length human growth hormone, AOD-9604 is a much smaller peptide designed for research into metabolic and lipolytic activity.
Research has focused primarily on how AOD-9604 may affect adipose tissue, fatty-acid metabolism, lipolysis, and energy expenditure.
AOD-9604 has also been investigated as a potential obesity treatment, although its clinical development for this purpose was discontinued after later trials failed to demonstrate sufficient weight-loss efficacy.
AOD-9604 Molecular Structure
AOD-9604 is a synthetic 16-amino-acid peptide investigated in research involving lipid metabolism, lipolysis, adipose tissue biology, and related metabolic pathways.
Its molecular identity and structural characteristics are important areas of analytical research. For the complete amino-acid sequence, molecular formula, molecular weight, and structural analysis, see our dedicated guide: AOD-9604 Molecular Structure, Sequence, Formula & Molecular Weight
AOD-9604 Mechanism of Action
AOD-9604 has been investigated primarily in relation to lipolysis, adipose tissue biology, fatty-acid metabolism, and related metabolic pathways.
Preclinical research has examined changes in lipolytic activity, body weight, fat accumulation, energy expenditure, and fat oxidation. Research has also explored possible involvement of beta-adrenergic signaling.
The precise mechanism remains an area of scientific investigation, and findings from cellular and animal models should not be interpreted as proof of equivalent effects in humans.
For a detailed review of the proposed mechanisms and experimental findings, see: AOD-9604 Mechanism of Action: Lipolysis, Adipocyte & Metabolic Research
AOD-9604 and Lipolysis Research
Lipolysis is the process through which stored triglycerides in adipocytes are broken down into fatty acids and glycerol.
In obese animal models, AOD-9604 treatment was associated with increased lipolytic activity and changes in body-weight gain. These findings provided the basis for subsequent research into its potential metabolic applications.
AOD-9604 Studies and Clinical Evidence
AOD-9604 has been investigated in both preclinical and human research, with studies examining its potential effects on lipid metabolism, adipose tissue biology, body weight, and related metabolic pathways.
Preclinical Research
Animal and laboratory studies have investigated AOD-9604 in areas including lipolysis, fat metabolism, adipose tissue biology, energy expenditure, and body-weight changes.
These findings provided a basis for further investigation but do not establish equivalent effects in humans.
Human Research
AOD-9604 was also evaluated in human clinical research for obesity. Studies examined different doses, safety, tolerability, weight-related outcomes, and metabolic measures.
Later clinical development did not demonstrate sufficient weight-loss efficacy compared with placebo, and development of AOD-9604 for obesity was discontinued.
For the detailed study history, human trials, and preclinical evidence, see: AOD-9604 Studies: Human Trials, Preclinical Research & Evidence
AOD-9604 vs Human Growth Hormone
AOD-9604 and human growth hormone are different molecules with different biological profiles.
Human growth hormone is a 191-amino-acid protein hormone with broad biological activity, whereas AOD-9604 is a much smaller synthetic peptide investigated primarily in metabolic and lipolysis-related research.
Because their structures and biological activities differ, findings from human growth hormone research should not automatically be applied to AOD-9604.
For a detailed comparison of their structure, mechanism, and research evidence, see: AOD-9604 vs Human Growth Hormone: Structure, Mechanism & Research
AOD-9604 Stability and Handling Research
Like other synthetic peptides, AOD-9604 can be evaluated for chemical stability under different storage and handling conditions.
Important factors in peptide stability research include:
- Temperature
- Moisture
- Light exposure
- Solution conditions
- Repeated handling
- Oxidation
- Freeze-thaw exposure
- Storage duration
Stability should be evaluated using appropriate analytical methods rather than assumed from the peptide’s appearance or formulation.
For more information about analytical considerations and peptide stability research, see: AOD-9604 Stability: Storage, Handling & Degradation Research
AOD-9604 COA and Analytical Testing
A Certificate of Analysis (COA) provides batch-specific analytical information about a research compound.
For AOD-9604, relevant analytical information can include:
- Batch or lot identification
- HPLC purity
- Mass spectrometry results
- Expected molecular mass
- Identity testing
- Testing laboratory
- Test date
- Additional quality-control measurements
HPLC purity and mass spectrometry answer different questions. HPLC can provide information about chromatographic purity, while mass spectrometry can help confirm molecular identity.
A COA should therefore be evaluated as analytical documentation for a specific batch rather than treated as proof of clinical efficacy or human-use safety.
See: AOD-9604 COA: How to Read Purity, HPLC & Mass Spectrometry Results
AOD-9604 Research Limitations
The evidence base for AOD-9604 has important limitations.
Much of the mechanistic research comes from cellular and animal models. These studies are useful for investigating biological pathways but cannot establish that the same effects will occur in humans.
Human clinical research also produced an important negative result. The larger obesity development program failed to demonstrate sufficient weight-loss efficacy compared with placebo, leading to discontinuation of development for that indication.
For this reason, claims about AOD-9604 should distinguish between:
Preclinical findings
What has been observed in cells or animal models.
Clinical findings
What has been observed in human studies.
Established conclusions
What the overall evidence can reasonably support.
This distinction is particularly important when discussing AOD-9604 in the context of weight loss or metabolic health.
AOD-9604 Research vs Other Metabolic Peptides
AOD-9604 is only one of several peptides investigated in metabolic research.
Different compounds can have substantially different molecular structures, targets, mechanisms, and levels of clinical evidence.
Comparisons may include:
- AOD-9604
- CJC-1295
- Ipamorelin
- Tirzepatide
- Retatrutide
- Cagrilintide
These compounds should not be treated as interchangeable. A meaningful comparison should consider molecular class, biological targets, mechanism, research model, clinical evidence, and development status.
See: AOD-9604 vs Other Metabolic Peptides: Research Comparison
Is AOD-9604 Approved for Weight Loss?
AOD-9604 was investigated as a potential obesity treatment, but its development for obesity was discontinued after clinical trials failed to demonstrate sufficient efficacy.
Therefore, AOD-9604 should not be presented as an established or approved weight-loss treatment.
The distinction between experimental research and approved medical treatment is important when interpreting AOD-9604 literature.
AOD-9604 Research Summary
AOD-9604 is a 16-amino-acid synthetic peptide investigated primarily for lipolytic and metabolic effects.
Research has reported activity involving adipose tissue metabolism, lipolysis, fat oxidation, and related metabolic pathways, particularly in preclinical models.
The molecular identity of AOD-9604 is well characterized, including its 16-amino-acid sequence, molecular formula, molecular weight, and disulfide-linked structure.
However, the clinical evidence is more limited. Although AOD-9604 progressed into human obesity studies, its development for that indication was discontinued after larger trials failed to demonstrate sufficient weight-loss efficacy.
For research purposes, AOD-9604 remains a useful subject for investigating peptide structure, adipocyte biology, lipolytic signaling, metabolic pathways, analytical characterization, and peptide stability.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic 16-amino-acid peptide studied for lipolytic, adipose-tissue, and metabolic effects.
What is the amino acid sequence of AOD-9604?
The reported sequence is YLRIVQCRSVEGSCGF.
What is the molecular weight of AOD-9604?
The molecular weight listed for AOD-9604 is approximately 1815.1 g/mol.
What is the molecular formula of AOD-9604?
The molecular formula is C78H123N23O23S2.
Has AOD-9604 been studied in humans?
Yes. AOD-9604 was evaluated in human clinical studies, including larger trials investigating its potential for obesity.
Did AOD-9604 clinical trials prove effective for weight loss?
No. Although some earlier studies produced encouraging findings, the larger obesity development program did not demonstrate sufficient weight-loss efficacy compared with placebo, and development for obesity was discontinued.
Is AOD-9604 the same as human growth hormone?
No. AOD-9604 is a much smaller synthetic peptide associated with the lipolytic region of human growth hormone, while human growth hormone is a 191-amino-acid protein hormone with broader biological activity.
What does AOD-9604 research focus on?
Research has focused on lipolysis, adipocyte biology, fatty-acid metabolism, fat oxidation, energy expenditure, and related metabolic pathways.
How is AOD-9604 analyzed in laboratory research?
Analytical characterization can include HPLC for chromatographic purity and mass spectrometry for molecular identity, along with other batch-specific quality-control tests.
Is AOD-9604 an approved weight-loss medication?
No. Its development as an obesity treatment was discontinued after clinical research failed to demonstrate sufficient efficacy.
7 comments